13D Filing: James E. Flynn and Homology Medicines Inc (FIXX)

Page 20 of 20

Page 20 of 20 – SEC Filing

CUSIP No.  438083107

Exhibit Index

Exhibit

Number

Description
Exhibit 1 Amended and Restated Investor Rights Agreement, dated July
28, 2017, by and among Homology Medicines, Inc. and the investors named therein (incorporated by reference to Exhibit 4.1 to the
Company’s Form S-1/A filed with the Securities and Exchange Commission on March 23, 2018).
Exhibit 99.1 Joint Filing Agreement dated as of April 6, 2018 by and among
the Reporting Persons.*
Exhibit 99.2 Power of Attorney previously filed as Exhibit 24 to a Form
3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special
Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III,
L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield
Management Company, L.P., and James E. Flynn.

* Filed herewith.

Follow Q32 Bio Inc. (NASDAQ:QTTB)

Page 20 of 20